Two pairings of private equity groups are considering bids for Stada that would value the German generic drugmaker at up to 4.8 billion euros ($5.1 billion) including debt, people familiar with the matter told Reuters on Monday.
Advent and Permira are talking about a joint offer, two of the people said, confirming a report in the Frankfuter Allgemeine Zeitung.
Bain Capital und Cinven, who had previously separately signalled interest, have also joined forces, three sources said.
READ FULL ARTICLE HERE
